Refine by
Cell Therapeutic Suppliers & Manufacturers
68 companies found
based inParis, FRANCE
Curadigm is an early-stage company focused on shifting the paradigm of therapeutic clearance, bioavailability, and efficacy to improve treatment outcomes for millions of patients. Curadigm was spun-off from Nanobiotix, a late-stage clinical company, ...
Curadigm’s technology was developed to address a critical challenge facing intravenously administered therapeutics: How can you efficiently deliver a drug to your tissue of interest without rapid clearance? To address this, we ...
based inSan Francisco, CALIFORNIA (USA)
Vetherapy is a team of scientists, bioengineers, veterinarians and entrepreneurs on a mission to bring stem cell therapies to treat complex and challenging diseases for pet. Vetherapy stem cell therapies are the result of nearly 2 decades of ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
APVO436 is an optimized ADAPTIR bispecific antibody candidate designed to redirect T-cell cytotoxicity through the dual targeting of CD3, a T-cell co-receptor that promotes cytotoxicity, and CD123, a cell surface receptor highly expressed in several ...
based inSeattle, WASHINGTON (USA)
Lumen Bioscience discovers, develops, and manufactures biologic drug candidates for highly prevalent diseases-many of which currently lack effective treatments. The company’s unique drug development and manufacturing platform offers the potential to ...
We design and manufacture therapeutics against disease targets that have been inaccessible to the biopharmaceutical industry because of the astonishingly high cost of traditional methods. Now, for the first time, Lumen can make antibodies and other ...
based inOxford, UNITED KINGDOM
Vaccitech is a clinical stage T cell immunotherapy and vaccine company developing products to treat and prevent infectious disease and cancer. The company’s proprietary heterologous prime-boost platform comprises Chimpanzee Adenovirus Oxford ...
The patented Vaccitech adenovirus vectors are known as chimpanzee adenovirus Oxford 1 and 2 (ChAdOx1 and ChAdOx2), and are in the group E simian adenovirus family, similar to the widely-studied chimpanzee adenovirus 63. These viruses have been ...
based inPaddington, AUSTRALIA
Regeneus is an Australian biotechnology company aiming to improve the quality of life of the hundreds of millions of patients worldwide suffering from long and short term pain. Pain and inflammation are responsible for a series of events leading to ...
Regeneus manufactures MSC’s under strict quality standards. In accordance with the guidelines set by the International Society for Cellular Therapy (ISCT) and our rigorous testing we are easily able to identify MSC donor ...
based inDidcot, UNITED KINGDOM
We design, develop and manufacture nanofibrous biomaterials for medical devices and regenerative medicine. Our technology platform is built on electrospinning and associated processing technologies. We are supporting clients with material ...
Significant advances in recent years mean that cell therapy is becoming a clinical reality. The unique characteristics of electrospun materials, including scaleability, minimal immunogenicity, regulatory familiarity and the ability to create a ...
based inCottesloe, AUSTRALIA
Neuroscientific Biopharmaceuticals is an Australian public company (ASX:NSB) developing novel peptide-based pharmaceutical products that target a number of neurological disorders and diseases of the eye that have high unmet medical need. Our vision ...
Multiple indications with unmet medical need. “Our company goal is to create new products that reach their target in the brain and act as a protector against nerve cells injury. Currently, there are no approved drugs that can slow down or halt ...
based inDurham, NORTH CAROLINA (USA)
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable, bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. Humacyte ...
based inSan Diego, CALIFORNIA (USA)
Capricor is Developing Transformative Cell and Exosome-based Therapeutics for the Treatment and Prevention of Diseases. Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and ...
based inRimini, ITALY
Limfa Technologies srl is a company based in San Marino Republic that designs, develops, manufactures and distributes extremely innovative medical devices. In our vision the success is the natural result of rigorous scientific research, both ...
The fruit of Italian research, LIMFA Therapy is a medical device for non-invasive cellular stimulation, through ultra-weak, complex and patented magneto-electric fields which, by entering into bio-resonance with cellular ions, are able to accelerate ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several ...
based inFreiburg, GERMANY
CYTENA, the premier provider of single-cell dispensers, liquid handlers and live cell analyzers, started out in 2014 as a spin-off from the Laboratory for MEMS Applications and the Hahn-Schickard Institute in Freiburg, Germany. In 2019, CYTENA ...
Faster than Ever Before: By automating labor-intensive and time-consuming steps, the F.SIGHT 2.0 significantly streamlines Cell Line Development (CLD), Cell & Gene therapy, as well as Single-cell Omics workflows. The F.SIGHT 2.0 is the fastest ...
based inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
based inCalgary, ALBERTA (CANADA)
Hemostemix (TSX V:HEM; OTCQB:HMTXF) is a clinical-stage biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. Hemostemix’s proprietary platform technology is based on more ...
Hemostemix’s technology uses a patient’s own cells to treat that patient’s disease. The cornerstone of this autologous technology is a novel cell population within the blood called the synergetic cell population (SCP). The ...
based inCarlsbad, CALIFORNIA (USA)
ScienCell Research Laboratories is an expanding biotechnology company established in 1999. Our mission is to research and develop cell products for experimental use. ScienCell provides a variety of high quality normal human and animal cells, cell ...
based inHouston, TEXAS (USA)
cellvie is the leader in Therapeutic Mitochondria Transplantation (TMT). The team is seeking to bring about a novel treatment modality, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell. Therapeutic Mitochondria ...
based inMadison, WISCONSIN (USA)
Vascular diseases afflict hundreds of millions of people worldwide. Many patients do not respond to standard treatments. We are developing regenerative medicines to address these unmet needs. Vascugen is dedicated to revolutionizing the standard of ...
Development of complex iPSC-based therapeutics benefits from an engineering mindset. Each layer of the development and manufacturing process is considered part of the ‘Full Stack’ that leads to finished product. An integrated stepwise ...
based inSan Diego, CALIFORNIA (USA)
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary ...
based inBasel, SWITZERLAND
Nuclidium AG specializes in leveraging the unique properties of copper radionuclides in conjunction with tumor-specific molecules to enhance the precision, performance, and accessibility of targeted radiotherapy and diagnostics. Their proprietary ...
Nuclidium AG leverages the unique properties of copper radionuclides to advance precision radiotherapy and diagnostics. Their proprietary CuTrace™ platform combines copper nuclides with tumor-specific molecules, creating diagnostic and ...